Coya Therapeutics, Inc. Provides Business Update and Reports Q2 2023 Unaudited Financial Results

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced its financial results for the second quarter ended June 30, 2023,...

Related Keywords

United States ,American ,Fred Grossman ,Howard Berman ,Guillaume Doroth ,Michelle Frazier ,David Snyder ,Muscular Dystrophy Association Conference ,Coya Therapeutics Inc ,Alzheimer Association International Conference ,Nasdaq ,American Neurological Association ,Regulatory Affairs ,Company Scientific Advisory Board ,Coya Therapeutics ,Regulatoryt Cells ,Amyotrophic Lateral Sclerosis ,Dystrophy Association ,Symposia Neurodegeneration ,Biology Guiding ,Next Generation ,Tumor Necrosis Factor ,Positron Emission Tomography ,Association International Conference ,Chief Medical Officer ,Varun Swaminathan ,Chief Business Officer ,Senior Vice President ,Merit Cudkowicz ,Scientific Advisory ,Chief Executive Officer ,Initiated Phase ,Houston Methodist Hospital ,Stockholder Equity ,Months Ended June ,